

## **FOR IMMEDIATE RELEASE**

---

For more information, contact:

**Kevin M. Smith**  
President & CEO  
CID4  
[kevin.smith@cid4.com](mailto:kevin.smith@cid4.com)  
(720) 859-4043

### **All Colorado Institute for Drug, Device and Diagnostic Development Portfolio Companies Accepted to Present at the 2011 Rocky Mountain Life Science Investor and Partnering Conference**

*The Colorado Institute for Drug, Device and Diagnostic Development (CID4) announced that all four of its portfolio companies, Sophono, PeptiVir, VetDC and Flashback Technologies, have been accepted to present and participate in partnering discussions at the 2011 Rocky Mountain Life Science Investor and Partnering Conference.*

**Aurora, CO August 15, 2011** – The Colorado Institute for Drug, Device and Diagnostic Development (CID4), a 501(c)(3) not-for-profit entity focused on advancing the Colorado life science ecosystem through company creation and job growth, announced that all four of its portfolio companies, Sophono, PeptiVir, VetDC and Flashback Technologies, have been accepted to present and participate in partnering discussions at the 2011 Rocky Mountain Life Science Investor and Partnering Conference (RMLSIPC).

Organized by the Colorado BioScience Association, the RMLSIPC is the Rocky Mountain region's premiere investor and partnering conference, attracting venture capital funds, corporate venture funds and business development leaders from the largest global biopharmaceutical and medical device companies – all convening in Denver, CO September 21-23, 2011. The conference incorporates a robust and competitive company selection process that is filtered by a national committee of life science investors and business development executives. The selection committee recently released names of the thirty companies hand-picked to attend and present over the course of the three-day conference.

CID4's mission to advance the Colorado bioscience ecosystem through company creation and job growth is only partially fulfilled through project investment, it is the active management role that yields tangible progressive milestone-driven value, such as architecting early-stage company roadmaps and assisting in the raising of follow-on capital. Positioning a portfolio company in front of institutional capital and potential industry partners is a critical function played by CID4 management.

“We are excited to have all of our portfolio companies selected to present at the 2011 RMLSIPC. It was a very competitive process, inclusive of many well qualified companies, all of whom could not be chosen,” said Kevin M. Smith, President and CEO of CID4. “Having Sophono, PeptiVir, VetDC and Flashback Technologies participate speaks to the quality of technologies emerging from Colorado and validates the CID4 project selection process which is driven by the industry professionals who generously volunteer their time and expertise as members of CID4's Technical and Business Advisory Committee.”

## **FOR IMMEDIATE RELEASE**

---

“Our Association spearheads the investor and partnering conference every other year for the region. This is our second event, and we have been absolutely thrilled at the response from both companies applying to present and investors desiring to attend,” said Holli Riebel, President and CEO of the Colorado BioScience Association. “The selection of four CID4 Project companies to present at this year’s conference is a reflection of CID4’s role as more than just a source of investment capital, but also an active participant in the management of its Project companies.”

### **About Rocky Mountain Life Science Investor and Partnering Conference**

Held September 21-23, 2011 at the historic Brown Palace Hotel in Denver, CO the second Rocky Mountain Life Science Investor and Partnering Conference (RMLSIC) brings together leading investors, strategic partners, emerging companies and senior executives to cultivate partnerships. With twenty or more corporate and venture investors from Boston to San Francisco and points in between in attendance, the RMLSIC is the regions largest investor and partnering conference. Keynote speakers include Karin Hehenberger, MD, Ph.D. of the Juvenile Diabetes Foundation and Roy Davis, President of Johnson & Johnson Corporate Development. For more information and to register visit <http://www.cobioscience.com/RMLIPC>.

### **About the Colorado BioScience Association**

The Colorado BioScience Association (CBSA) is a not-for-profit corporation providing services and support for Colorado's growing biosciences industry. With more than 350 members, CBSA actively works to promote the growth of the industry by working for a better business environment, grow the state's biotech workforce, fight for policies that support a strong bioscience industry in the state and speak with a single voice on behalf of the industry. For more information visit <http://www.cobioscience.com>.

### **About the Colorado Institute for Drug, Device and Diagnostic Development**

Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visit <http://CID4.com>.

###